A semaglutide trial found 9% slower epigenetic aging, but the authors say it doesn't make anyone younger (universityofcalifornia.edu)
After 32 weeks, the semaglutide group showed a 9% slower pace of aging on the DunedinPACE clock and slowed PCGrimAge, which tracks mortality risk. The senior author's own caveat is explicit: 'We are not saying that semaglutide reverses aging.'
On HN, a geneticist said epigenetic clocks may simply read out things that don't affect healthspan.
Sign in to save